Abbott has obtained Health Canada licencing for its new glucose sensing technology FreeStyle Libre Flash Glucose Monitoring System for adults with diabetes.

The new system uses a disposable sensor that can be worn on the upper arm to read glucose levels for around 14 days, eliminating the need for fingerstick calibration.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

FreeStyle measures the glucose in interstitial fluid every minute via a small filament that is to be inserted beneath the skin and held in place using a small adhesive pad.

With every scan, the system provides real-time glucose results, glucose direction, and eight-hour historical trend. The reader retains data for approximately 90 days.

The visual snapshot of glucose fluctuations that occur during a day is delivered by the system as an ambulatory glucose profile (AGP), enabling a measure of hypoglycaemic and hyperglycaemic levels for accurate diabetes management.

"This technology not only transforms how people have been testing their glucose levels for decades, it also may support improved overall diabetes management."

Abbott Canada Diabetes Care general manager Badia Boudaiffa said: "Bringing FreeStyle Libre to the three million people living with diabetes across Canada is a major milestone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This technology not only transforms how people have been testing their glucose levels for decades, it also may support improved overall diabetes management."

Upon evaluation in the IMPACT clinical trial, the FreeStyle Libre system was found to allow diabetes patients to spend 38% less time in hypoglycaemia when compared to patients using standard self-monitoring of blood glucose systems (SMBG).

The results further indicated that the system enables better hypoglycaemia management without an increase in HbA1c levels.